$0.3900
At close: Nov 18, 3:56 PM EDT
$0.5291
0.1435.67%
After Hours: Nov 18, 9:10 AM EDT
Comments
Loading...
Seelos Therapeutics Inc COM PAR NEW $0.001 Analyst Ratings
SEELOTC
Seelos Therapeutics Inc COM PAR NEW $0.001 Analyst Ratings and Price Targets | OTC:SEEL | Benzinga
Seelos Therapeutics Inc COM PAR NEW $0.001 has a consensus price target of $2.5 based on the ratings of 4 analysts. The high is $4 issued by BTIG on May 15, 2023. The low is $1 issued by Benchmark on September 21, 2023. The 3 most-recent analyst ratings were released by Benchmark, Cantor Fitzgerald, and Cantor Fitzgerald on September 21, 2023, August 22, 2023, and August 15, 2023, respectively. With an average price target of $1.67 between Benchmark, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 327.35% upside for Seelos Therapeutics Inc COM PAR NEW $0.001 from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
BTIG
1calculated from analyst ratings
Analyst Ratings for Seelos Therapeutics Inc COM PAR NEW $0.001
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 09/22/2023 | Buy Now | — | Guggenheim | Yatin Suneja47% | — | Downgrade | Buy → Neutral | Get Alert |
| 09/21/2023 | Buy Now | 156.41% | Benchmark | Bruce Jackson39% | $15360 → $3840 | Maintains | Speculative Buy | Get Alert |
| 09/21/2023 | Buy Now | — | Guggenheim | Yatin Suneja47% | — | Downgrade | Buy → Neutral | Get Alert |
| 09/21/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan68% | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/22/2023 | Buy Now | 412.82% | Cantor Fitzgerald | Charles Duncan68% | → $7680 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | Buy Now | 412.82% | Cantor Fitzgerald | Charles Duncan68% | → $7680 | Reiterates | Overweight → Overweight | Get Alert |
| 06/23/2023 | Buy Now | 412.82% | Cantor Fitzgerald | Charles Duncan68% | → $7680 | Reiterates | Overweight → Overweight | Get Alert |
| 06/23/2023 | Buy Now | 925.64% | Benchmark | Bruce Jackson39% | $15360 → $15360 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 05/16/2023 | Buy Now | 412.82% | Cantor Fitzgerald | Charles Duncan68% | $11520 → $7680 | Maintains | Overweight | Get Alert |
| 05/15/2023 | Buy Now | 925.64% | BTIG | Robert Hazlett34% | $42240 → $15360 | Maintains | Buy | Get Alert |
| 03/30/2023 | Buy Now | 2720.51% | BTIG | Robert Hazlett34% | → $42240 | Maintains | Buy | Get Alert |
| 03/24/2023 | Buy Now | 925.64% | Benchmark | Bruce Jackson39% | $23040 → $15360 | Maintains | Buy | Get Alert |
| 02/13/2023 | Buy Now | 2976.92% | BTIG | Robert Hazlett34% | $46080 → $46080 | Maintains | Buy | Get Alert |
| 04/28/2022 | Buy Now | 2976.92% | BTIG | Robert Hazlett34% | → $46080 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL) stock?
The latest price target for Seelos Therapeutics Inc COM PAR NEW $0.001 (OTC:SEEL) was reported by Guggenheim on September 22, 2023. The analyst firm set a price target for $0.00 expecting SEEL to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL)?
The latest analyst rating for Seelos Therapeutics Inc COM PAR NEW $0.001 (OTC:SEEL) was provided by Guggenheim, and Seelos Therapeutics Inc COM PAR NEW $0.001 downgraded their neutral rating.
When was the last upgrade for Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL)?
There is no last upgrade for Seelos Therapeutics Inc COM PAR NEW $0.001
When was the last downgrade for Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL)?
The last downgrade for Seelos Therapeutics Inc COM PAR NEW $0.001 happened on September 22, 2023 when Guggenheim changed their price target from N/A to N/A for Seelos Therapeutics Inc COM PAR NEW $0.001.
When is the next analyst rating going to be posted or updated for Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seelos Therapeutics Inc COM PAR NEW $0.001, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seelos Therapeutics Inc COM PAR NEW $0.001 was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
Is the Analyst Rating Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL) correct?
While ratings are subjective and will change, the latest Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL) rating was a downgraded with a price target of $0.00 to $0.00. The current price Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL) is trading at is $0.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
